DEXAD trial of dexamfetamine formulations in adults with ADHD and moderate to severe depression

Phase 2, randomised, double-blind trial of atomoxetine and adenosine-5′-monophosphate in attention deficit hyperactivity disorder (ADHD) and major depressive disorder (MDD) (3 arms), sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology. Primary endpoint: Incidence of adverse events in active treatment groups versus placebo. Planned start May 2025; status: authorised.